Non-Hodgkins Lymphoma Archives -

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for

Kite cues up first EMA okay for mantle cell lymphoma CAR-T

https://pharmaphorum.com/news/kite-cues-up-first-ema-okay-for-mantle-cell-lymphoma-car-t/

With more competition looming for its CAR-T therapy Kymriah, Novartis has pointed to new data that show the

Real-world data backs Kymriah’s safety profile, says Novartis

https://pharmaphorum.com/news/real-world-data-backs-kymriahs-safety-profile-says-novartis/

There’s been a slew of scientific data coming from the American Society for Hematology (ASH) conference, but promising

Early data from Roche’s NHL drug mosunetuzumab steals the show at ASH

https://pharmaphorum.com/news/early-data-from-roches-mosunetuzumab-steals-the-show-at-ash/

Celgene has added another new indication for its blood cancer blockbuster Revlimid, with the FDA approving its use

Celgene bags FDA okay for Revlimid combo in lymphoma

https://pharmaphorum.com/news/celgene-bags-fda-okay-for-revlimid-combo-in-lymphoma/

The European Commission has approved Poteligeo (mogamulizumab), a treatment for rare types of non-Hodgkin’s lymphoma. The drug is

EU approves Kyowa Kirin’s drug for rare lymphoma

https://pharmaphorum.com/news/eu-approves-kyowa-kirins-drug-for-rare-lymphoma/

It looks increasingly likely that Roche’s cancer blockbuster Rituxan (rituximab) will face competition from a cheaper biosimilar in

Celltrion/Teva Rituxan biosimilar edges closer to US approval

https://pharmaphorum.com/news/celltrion-teva-rituxan-biosimilar-edges-closer-to-us-approval/

Kite looks all set for a regulatory approval later this year for its CAR-T drug KTE-CI9 after the

Great news for Kite after CAR-T success in cancer patients

https://pharmaphorum.com/news/good-news-kites-car-t-drug-lymphoma/

Non-Hodgkins Lymphoma